To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 6)
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Sponsor: GlaxoSmithKline
This PHASE1/PHASE2 trial investigates Multiple Myeloma and is currently completed. GlaxoSmithKline leads this study, which shows 27 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
27 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 22 earlier versions
-
Jun 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Phase: PHASE2 → PHASE1_PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE2 → PHASE1_PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — May 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — May 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Iqvia Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .